Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol

Contraception

Volumn 63, Issue 2, 2001, Pages 71-76

  Boyd, Rebecca A ^a   Zegarac, Elizabeth A ^a   Posvar, Edward L ^a   Flack, Mary R ^a  

^a PFIZER INC   (United States)

Author keywords

Ethinyl estradiol; Free testosterone; Norethindrone acetate; Pharmacokinetics; Sex hormone binding globulin

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GESTAGEN; LIPID; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACNE; ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL CONTRACEPTION; STEADY STATE;

ADULT; ANDROGENS; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; KINETICS; NORETHINDRONE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 0035070223     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00179-2     Document Type: Article

References (26)

1. Measurements of androgenicity. The spectrum of progestogen activity
2. The androgenicity of progestational agents
3. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin
4. A pharmacodynamic and pharmacokinetic study of the Chinese No. 1 pill
5. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women
6. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: A randomized trial
7. The effect of a low-dose oral contraceptive on serum testosterone levels in polycystic ovary disease
8. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome
9. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone
10. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel
11. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel
12. Single and multiple administration of a new triphasic oral contraceptive to women: Pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum
13. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum
14. A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive
15. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives
16. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
17. Progestational and androgenic receptor binding affinities and in vivo activities of noregestimate and other progestins
18. Plasma protein binding of norethisterone
19. A comparison of the potencies and activities of progestogens used in contraceptives
20. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids
21. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: Recent advances
22. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol
23. Effect of contraceptive steroids on serum levels of sex hormone binding globulin and ceruloplasmin
24. A comparison of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel
25. Effect of low-dose oral contraceptives on androgenic markers and acne
26. Effects of sex steroids on skin 5α-reductase activity in vitro